Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 ustekinumab induction therapy study in moderately to severely active Crohn's disease
NL-OMON39728Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ustekinumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response at Week 6. Started Dec 2012; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON39728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39728.